Orcrist Bio Inc. has announced that it has received permission to study their safety in Phase I open-label single ascending dose in healthy men on HYC750 volunteers, through the competent European authority in Seville (Spain ). The aim of this study is to evaluate the safety, tolerance, pharmacokinetics and pharmacodynamics (induction of hematopoiesis) of HYC750, a formulation patent protection hialuronano.
"The approval of our Phase I clinical trial by the European authorities is another outstanding achievement by Orcrist achieved," said Dr. Brett Schonekess, director general and CEO of Orcrist. "With this approval, we are now positioned correctly to move within INPEC as our clinic, carrying out the future development of HYC750 to confirm the safety profile and provide a clear illustration of the properties for mobilization of stem cells. Finally, this is an important step towards advancing the development of our product as a treatment for the removal of white blood cells associated with chemotherapy. "